Pearl Shirley Huang
Director/Board Member bei WATERS CORPORATION
Vermögen: 479 168 $ am 31.03.2024
Profil
Pearl Shirley Huang was the founder of BeiGene Ltd., a company founded in 2010 where she held the title of Chief Scientific Officer from 2010 to 2012.
She is currently the Chief Executive Officer at Dunad Therapeutics Ltd., starting in 2022.
She is also a Director at BB Biotech AG since 2022 and an Independent Director at Waters Corp.
since 2021.
Additionally, she serves as a Director at MIT Corp.
(United States).
Previously, she was the President, Chief Executive Officer & Director at Cygnal Therapeutics, Inc. from 2019 to 2022.
She also held the position of Chairman at Roche Innovation Center Copenhagen A.
From 2019 to 2022, she was a Director at KSQ Therapeutics, Inc. Prior to that, she was the Senior VP & Global Head-Therapeutic Modalities at F.
Hoffmann-La Roche Ltd.
from 2014 to 2018 and Vice President at GSK Plc from 2012 to 2014.
She has also served as an Advisor Partner at Flagship Pioneering.
Dr. Huang completed her undergraduate studies at Massachusetts Institute of Technology and holds a doctorate degree from Princeton University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
WATERS CORPORATION
0,00% | 28.03.2024 | 1 392 ( 0,00% ) | 479 168 $ | 31.03.2024 |
Aktive Positionen von Pearl Shirley Huang
| Unternehmen | Position | Beginn |
|---|---|---|
| WATERS CORPORATION | Director/Board Member | 01.01.2021 |
| BB BIOTECH AG | Director/Board Member | 17.03.2022 |
MIT Corp. (United States)
 MIT Corp. (United States) Other Consumer ServicesConsumer Services MIT Corp. (US) owns and operates as a trust. The corporation and its committees have responsibility for reviewing and providing guidance on strategic directions, approving annual budgets and exercising long-term fiduciary responsibility. The company was founded in 1861 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Dunad Therapeutics Ltd.
 Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Chief Executive Officer | 28.06.2022 |
Ehemalige bekannte Positionen von Pearl Shirley Huang
| Unternehmen | Position | Ende |
|---|---|---|
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Director/Board Member | 23.09.2022 |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | 18.05.2022 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 30.04.2022 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.12.2018 |
| GSK PLC | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Pearl Shirley Huang
| Massachusetts Institute of Technology | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BB BIOTECH AG | Finance |
| WATERS CORPORATION | Health Technology |
| GSK PLC | Health Technology |
| BEIGENE, LTD. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
MIT Corp. (United States)
MIT Corp. (United States) Other Consumer ServicesConsumer Services MIT Corp. (US) owns and operates as a trust. The corporation and its committees have responsibility for reviewing and providing guidance on strategic directions, approving annual budgets and exercising long-term fiduciary responsibility. The company was founded in 1861 and is headquartered in Cambridge, MA. | Consumer Services |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Health Technology |
Cygnal Therapeutics, Inc.
Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Health Technology |
